SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that preclinical data evaluating the mechanism of action and therapeutic potential of NU206 (R-spondin1) for chemotherapy or radiation-induced oral mucositis, and preclinical data evaluating recombinant nematode anticoagulant protein c2 (rNAPc2) in mouse models of colorectal cancer, will be presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting, in San Diego, CA, April 12-16, 2008.
The presentation details are as follows:
Date/Time: Sunday, April 13, 2008, 1:00 - 5:00 p.m. PT
Poster Title (#1495): R-spondin1 protects mice from chemotherapy or radiation-induced oral mucositis by activating canonical Wnt/beta-catenin pathway
Location: Poster Board #2, Section 32, Exhibit Hall B-F, San Diego Convention Center
Date/Time: Wednesday, April 16, 2008, 8:00 a.m. - 12:00 p.m. PT
Poster Title (#5698): rNAPc2 inhibits colorectal cancer in mouse models through tissue factor
Location: Poster Board #11, Section 31, Exhibit Hall B-F, San Diego Convention Center
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo’s development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.
This press release contains “forward-looking statements,” which include statements regarding the timing, progress and anticipated completion of Nuvelo’s clinical stage and research programs, the anticipated availability of top-line data, projected operating expenses and cash usage and the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward- looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo’s filings with the SEC, including without limitation Nuvelo’s annual report on Form 10-K for the year ended December 31, 2007 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.
CONTACT: Lee Bendekgey, SVP, CFO and General Counsel of Nuvelo, Inc.,
+1-650-517-8358, lbendekgey@nuvelo.com; or Nicole Foderaro of WeissComm
Partners, +1-415-946-1058, nfoderaro@wcpglobal.com, for Nuvelo, Inc.
Web site: http://www.nuvelo.com//
